HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (55) Citing Articles via Google Scholar Google Scholar Articles by Bohlender, J. M. Articles by Wolf, G. Search for Related Content PubMed PubMed Citation Articles by Bohlender, J. M. Articles by Wolf, G.

INVITED REVIEW

Advanced glycation end products and the kidney

Department of Internal Medicine III, Friedrich-Schiller-University, Jena, Germany

Advanced glycation end products (AGEs) are a heterogeneous group of protein and lipids to which sugar residues are covalently bound. AGE formation is increased in situations with hyperglycemia (e.g., diabetes mellitus) and is also stimulated by oxidative stress, for example in uremia. It appears that activation of the renin-angiotensin system may contribute to AGE formation through various mechanisms. Although AGEs could nonspecifically bind to basement membranes and modify their properties, they also induce specific cellular responses including the release of profibrogenic and proinflammatory cytokines by interacting with the receptor for AGE (RAGE). However, additional receptors could bind AGEs, adding to the complexity of this system. The kidney is both: culprit and target of AGEs. A decrease in renal function increases circulating AGE concentrations by reduced clearance as well as increased formation. On the other hand, AGEs are involved in the structural changes of progressive nephropathies such as glomerulosclerosis, interstitial fibrosis, and tubular atrophy. These effects are most prominent in diabetic nephropathy, but they also contribute to renal pathophysiology in other nondiabetic renal diseases. Interference with AGE formation has therapeutic potential for preventing the progression of chronic renal diseases, as shown from data of animal experiments and, more recently, the first clinical trials.

RAGE; diabetic nephropathy; progression of renal disease; inflammation; glycoxidation

This article has been cited by other articles:

				G. Wolf, N. Muller, M. Busch, G. Eidner, C. Kloos, W. Hunger-Battefeld, and U. A Muller Diabetic foot syndrome and renal function in type 1 and 2 diabetes mellitus show close association Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1896 - 1901. [Abstract] [Full Text] [PDF]

				R. D. Semba, L. Ferrucci, K. Sun, K. V. Patel, J. M. Guralnik, and L. P. Fried Elevated serum advanced glycation end products and their circulating receptors are associated with anaemia in older community-dwelling women Age Ageing, May 1, 2009; 38(3): 283 - 289. [Abstract] [Full Text] [PDF]

				C. Ruster, T. Bondeva, S. Franke, M. Forster, and G. Wolf Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2179 - 2191. [Abstract] [Full Text] [PDF]

				P. R. Reynolds, S. D. Kasteler, M. G. Cosio, A. Sturrock, T. Huecksteadt, and J. R. Hoidal RAGE: developmental expression and positive feedback regulation by Egr-1 during cigarette smoke exposure in pulmonary epithelial cells Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1094 - L1101. [Abstract] [Full Text] [PDF]

				S. Ohtomo, M. Nangaku, Y. Izuhara, S. Takizawa, C. v. Y. d. Strihou, and T. Miyata Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1166 - 1172. [Abstract] [Full Text] [PDF]

				C. Tatone, F. Amicarelli, M. C. Carbone, P. Monteleone, D. Caserta, R. Marci, P. G. Artini, P. Piomboni, and R. Focarelli Cellular and molecular aspects of ovarian follicle ageing Hum. Reprod. Update, March 1, 2008; 14(2): 131 - 142. [Abstract] [Full Text] [PDF]

				P. Boor, K. Sebekova, T. Ostendorf, and J. Floege Treatment targets in renal fibrosis Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3391 - 3407. [Full Text] [PDF]

				M. He, H. Kubo, K. Ishizawa, A. E. Hegab, Y. Yamamoto, H. Yamamoto, and M. Yamaya The role of the receptor for advanced glycation end-products in lung fibrosis Am J Physiol Lung Cell Mol Physiol, December 1, 2007; 293(6): L1427 - L1436. [Abstract] [Full Text] [PDF]

				S. Bengmark Advanced Glycation and Lipoxidation End Products-Amplifiers of Inflammation: The Role of Food JPEN J Parenter Enteral Nutr, September 1, 2007; 31(5): 430 - 440. [Abstract] [Full Text] [PDF]

				C. Mallidis, I. Agbaje, D. Rogers, J. Glenn, S. McCullough, A. B. Atkinson, K. Steger, A. Stitt, and N. McClure Distribution of the receptor for advanced glycation end products in the human male reproductive tract: prevalence in men with diabetes mellitus Hum. Reprod., August 1, 2007; 22(8): 2169 - 2177. [Abstract] [Full Text] [PDF]

				S. Lee, W. Kim, S.-O. Moon, M. J. Sung, D. H. Kim, K. P. Kang, K. Y. Jang, S. Y. Lee, B. H. Park, G. Y. Koh, et al. Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes Nephrol. Dial. Transplant., February 1, 2007; 22(2): 396 - 408. [Abstract] [Full Text] [PDF]